CellCentric raises $220 million for multiple myeloma pill

9 articles · Updated · Endpoints News · May 6

The funding is aimed at bringing the drug to market for multiple myeloma patients who have exhausted all other treatment options.
The company, described as a 22-year-old transatlantic biotech, is seeking to advance development and commercialisation of the pill.
The raise underscores investor backing for therapies targeting hard-to-treat blood cancers and late-line patients with limited remaining options.

After a $220M funding win, is this biotech's cancer drug on the fast track to a 2027 IPO?

Can a daily pill truly challenge complex infusion therapies for the deadliest blood cancers?

A 60% response rate for a new myeloma pill sounds promising, but what are the hidden patient risks?